# Intoto Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/intoto-biotech

- Industry: Medical Devices & Equipment
- Headquarters: Fuqing, China
- Website: www.intotobiotech.com
- Latest round: Series A (Aug 3, 2026)
- Investors on record: 2

## About

Based in Fujian, China, and founded in 2022, Mingzhun Medical Technology (Fuzhou) Co., Ltd., trading as Intoto Biotech, operates as a provider of optical medical equipment that provides 3D pathology imaging technology platform. In August 2026, Intoto Biotech raised a series A funding led by Huafu Capital, with participation from other investors.

The company has developed a 3D pathology imaging technology platform. Its core products include the Mingzhun Pano One system, which can be used for large biological sample imaging, 3D pathology imaging, embryo, 3D cell and organoid imaging, etc.

The company generates revenue by providing optical microscopy equipment.

The company will use the latest funding to advance the registration filing and clinical trials of the company's 3D pathology imaging system, drive market promotion for its clinical product lines, and support scientific research services as well as the ongoing R&D of next-generation products.

## Funding rounds

- Series A, Aug 3, 2026 — Huafu Capital
- Angel, May 24, 2023 — Proxima Ventures

## Investors

- Proxima Ventures (https://capitalatlas.ai/funds/proxima-ventures) — Angel
- Huafu Capital (https://capitalatlas.ai/funds/huafu-capital) — Series A